Rheumatic diseases are a group of challenging but fascinating disorders affecting multiple organ systems, and can be trickier in the pediatric population. Much have progressed in this field overtime, as such, the latest knowledge was summarized and presented in this issue, including the basic disease pathogeneses, diagnostic and evaluation tools, and management experiences.
Update in classification and diagnosis criteria
In this section, the juvenile idiopathic arthritis (JIA) and the systemic lupus erythematosus (SLE) will be the main focus. Other kinds of diseases will be less mentioned. The present classification criteria for JIA, which requires starting before 16 years of age and a rigorous exclusion of other known causes of chronic arthritis, was proposed by the International League of Associations for Rheumatology in 2001, and serves well to unify the terminology across Europe and North America [1] . Recently, Pediatric Rheumatology International Trials Organization (PRINTO) proposed a new, homogeneous list of JIA disorders for better terminology unification and characterization. It is under test by centers worldwide and the details would be published in the following years. Macrophage activation syndrome (MAS), a potentially life-threatening complication of systemic inflammatory disorders, occurs most commonly in systemic JIA (sJIA). European League Against Rheumatism (EULAR), American College of Rheumatology (ACR), and the PRINTO collaboratively developed a set of classification criteria for MAS complicating sJIA in 2016. A febrile patient with known or suspected sJIA is classified as having MAS if the following criteria are met: ferritin > 684 ng/mL and any two of the following: platelet count ≤ 181 × 10 9 /L; aspartate aminotransferase > 48 units/L; triglycerides > 156 mg/dL; fibrinogen ≤ 360 mg/dL [2] . However, MAS can develop quickly and sometimes be the first sign of sJIA, which requires early recognition and timely control of this serious complication. In this issue, Zou et al. gave us their opinions and recommendations [3] .
For SLE, the classification criteria experienced several rounds of modifications by different associations or groups, yielding different sensitivities and specificities. Previous SLE classifications include the ACR criteria, revised in 1997, and the Systemic Lupus International Collaborating Clinics criteria published in 2012. This year, the ACR and EULAR jointly published a new classification system for SLE, utilizing a point system designed for 22 signs and symptoms [4] . A minimum score of ten points plus presence of an antinuclear antibody titer of at least 1:80 on human epithelial-2-positive cells without alternative diagnoses can fall into the diagnosis category. These new classifications demonstrated 96.2% sensitivity and 94.43% specificity, which can more accurately classify SLE. However, this new system was mainly done in adult SLE patients, and a more thorough validation should be made in pediatric SLE patients.
Most of the present criteria for pediatric rheumatic diseases were launched by EULAR, ACR or PRINTO. However, a new European project called the Single Hub and Access point for pediatric Rheumatology in Europe, launched from 2013 involving the pediatric rheumatology networks in all European Union member states and candidate member states have developed several good recommendations for pediatric rheumatic diseases such as pediatric SLE, juvenile dermatomyositis (JDM), pediatric antiphospholipid syndrome, and rare pediatric vasculitides. The recommendations and guidelines mentioned above were mainly designed for European patients, so their generalization in other regions and countries should be further validated.
Update in the assessment and monitoring tools
Accordingly, pediatric rheumatic diseases need close and careful assessment and monitoring. In recent years, some imaging techniques have been developed for assessment and monitoring disease activity and prognosis in pediatric rheumatic diseases such as ultrasound and magnet resonance imaging (MRI).
Ultrasonography has several advantages over other imaging modalities, including noninvasiveness, rapidity of performance, relatively low cost, ability to scan multiple organs at one time, repeatability, safety, and high acceptability among pediatric patients. In this issue, Zou et al. [5] reviewed the advances on the use of ultrasonography in pediatric rheumatic diseases. In JIA, ultrasound can be used to detect subclinical synovitis, to improve the classification of subtypes, to capture early articular damage, to monitor treatment response, and to guide intra-articular injections. Ultrasound can also monitor changes in echogenicity and cutaneous blood flow related to initial edema and later sclerosis, with high sensitivity and specificity. Combined histology-sonographic studies have found a range of dermal echogenicity patterns to be associated with active disease [6] . Ultrasound is also considered useful for evaluating musculoskeletal symptoms and assessing pathology of the parotid gland. However, it is an operator-dependent imaging technique. In the future, further research and educational efforts are required for expanding the use of ultrasound in children with rheumatic diseases.
MRI, as a sensitive and specific imaging method, is the only tool that would enable early diagnosis of pathologies with assessing simultaneously all features of synovial disease, especially, in the temporomandibular, hip, sacroiliac, and vertebral joints [7] . Dynamic contrast-enhanced MRI, which enables the analysis of the time course of signal changes following gadolinium administration, is also a useful tool in assessing JIA [8] . MRI has also been shown to be a useful imaging modality in managing JDM, and has been used to help diagnose the condition, monitor treatment and identify sites for muscle biopsy. Increased signal intensity reflecting inflammation within muscle correlates better with disease activity than elevation of creatine kinase levels [9] . A novel magnetic resonance imaging-based semi-objective scoring system was recently developed as a reliable biomarker of disease severity and response to therapeutic interventions in children with JDM [10] . MRI could also be very helpful for assessing musculoskeletal and neurological involvements in juvenile localized scleroderma, with the most common encountered deep tissue findings in extremity MRI of fascial thickening and enhancement [11] .
Based on several researches on JIA imaging, diffusionweighted imaging (DWI), a form of MRI based on measuring the random Brownian motion of water molecules within a voxel of tissue, has been recently introduced in JIA as a feasible, noninvasive functional imaging technique for the detection of synovial inflammation without intravenous contrast agent administration [12] . Li et al. [13] reported their findings of a retrospective cohort study describing the use of DWI in diagnosing synovitis in the knee joint of pediatric patients. The data from their analysis provided further evidences that single-shot echo-planar DWI could reliably visualize, or rule out the synovitis of the knee joint in pediatric patients. It is important for pediatricians to keep in mind that the skeletons of the children keep growing and thickness of the articular cartilage and ossification vary with age. However, there are still many questions await to be answered, such as when to perform an MRI, which imaging modality to use, and how many joints should be evaluated at a time.
Other than improvements in imaging techniques, some biomarkers are also promising to monitor disease activity. JIA activity is associated with activation of granulocytes and macrophages cells. Studies have shown that myeloid-related proteins, MRP-8/MRP-14 (S100A8/S100A9 heterodimer) and S100A12 can be used to determine disease activity and the risk of relapse as children with JIA and uveitis [14] . The serum levels of soluble interleukin-2 receptor a (CD25) and soluble CD163, which reflect the degree of activation and expansion of T cells and phagocytic macrophages, respectively, were found to represent valuable diagnostic parameters for MAS and to identify patients with subclinical forms; moreover, interleukin (IL)-18 is a candidate biomarker for response to therapy in sJIA [15] . Recently, various myositis-specific autoantibodies (MSAs) have been reported as specific disease markers of JDM [16] . The review by Wu et al. [17] shows that MSA profiles not only associate with specific clinical manifestations, but also associate with long-term outcomes. A relationship between MSAs and phenotypic features provided a tool for improving diagnosis, differentiating sub-classification, and predicting response to therapy and prognosis in JDM patients [18] . Although some of pediatric rheumatic disorder lack universal disease activity feature such as juvenile localized scleroderma, the Localized Scleroderma Cutaneous Assessment Tool and imaging methods have been applied to monitoring activity [19] .
Update in the management
Over the last decade, the understanding of the genetic and immunologic basis of autoimmune diseases has expanded, resulting in targeted biologic therapies that have changed the outcomes of children with rheumatic diseases such as JIA, SLE, JDM, and juvenile localized sclerosis.
For JIA, biological agents targeting IL-1 and IL-6 have been widely used, yielding good clinical responses. However, side effects of biological agents warrant attention as a recent study has shown that the use of anti-IL-1/IL-6 therapies may trigger lung disease in sJIA [20] .
Advances in high-throughput screening of small-molecule inhibitors accelerate the discovery of new and more specific therapeutic options. The recognition of the key role of interferons in the JDM and SLE is an important development [21] . Anifrolumab, a potential new treatment targeting interferon receptor, just successfully completed a phase three clinical trial called Treatment of Uncontrolled Lupus via the Interferon Pathway. Other than that, baricitinib, a drug targeting the JAK-STAT pathway thereby down-regulating interferon signaling and other proinflammatory cytokines, also showed efficacy in reducing arthritis and rash symptoms in a phase II clinical trial [22] . JAK inhibitor has also been considered as a potential new therapeutic strategy in refractory JDM, but lacking large-scale clinical trials [17] . The ultimate goal of more personalized treatment approaches remains some distance off.
Recent progress in the pathogenesis of pediatric SLE provided another new targeting therapy of belimumab (Benlysta) blocking the BLys system, which has been approved to treat adult SLE by several major countries including USA, UK, and China and also got approval for pediatric SLE patients in USA. Another aspect worthy of attention is the involvement of interferon signaling pathway during the development of SLE. Many studies have profoundly showed that nearly more than half of the active SLE patients present with remarkable interferon signature, which inspired the initiation of many clinical trials targeting interferon-α/β or interferon receptors [23] .
For juvenile localized scleroderma, systemic therapy is indicated if the lesion crosses any joint, or leads to potential cosmetic disfiguration or orthopedic problems, including synthetic and biologic disease-modifying antirheumatic drugs. Management decisions should be based on the particular subtype of disease, the site of lesions and on the degree of activity [6] . Autologous hematopoietic stem cell transplantation has also been assessed as a therapeutic option for severe rheumatic diseases, which could offer an effective and safe therapy and result in disease clinical remission and improvement of organ dysfunction.
In summary, much progress has been made over the past decades in the field of pediatric rheumatology, including but not limited to the pathogenesis, classification criteria, and therapies. Pediatric rheumatologists should keep up with the progress to increase the diagnostic accuracy and improve the prognosis of the patients.
